💨 Abstract

In the second quarter of 2025, Catalyst Pharmaceutical Partners reported a net income of $52.1 million, exceeding Wall Street's earnings expectations of 58 cents per share with adjusted earnings of 68 cents per share. The company's revenue of $146.6 million also surpassed forecasts, beating the expected $139.2 million. Catalyst anticipates full-year revenue between $545 million to $565 million.

Courtesy: WTOP Staff